Edinburgh, UK, 16th November 2018 / Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.
13
Nov
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
22
Oct
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa. Nearly 1000 senior executives, key decision makers and scientists congregated to share recent developments and advance cutting edge research in cell and gene therapy. This year’s conference saw a noticeable uptick in interest in next generation gene medicines and strategies to improve current products in development.
18
Oct
Edinburgh, 18th October, 2018 / Synpromics is pleased to announce positive data presented today by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.
17
Oct
Edinburgh, 17th October, 2018 / Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.